Rodhan Khthir, MD
Endocrinology, Diabetes & Metabolism · Bismarck, NDNPI 1164852646
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $663, 3.8 times the $177 reported in 2019.
Across 58 payments — averaging $29.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$210
- Dexcom, Inc.$181
- Sanofi-aventis U.S. LLC$168
- Amgen$159
- Novo Nordisk$146
- Abbott$120
- plus $747 from 17 others
What the payments were for
- Food & beverage$1,64995%
- Education$805%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 5 | $210 |
| Dexcom, Inc. | 5 | $181 |
| Sanofi-aventis U.S. LLC | 3 | $168 |
| Amgen | 9 | $159 |
| Novo Nordisk | 4 | $146 |
| Abbott | 2 | $120 |
| Boehringer Ingelheim | 3 | $107 |
| Nevro Corp. | 1 | $99 |
| Insulet Corporation | 3 | $81 |
| Bayer | 5 | $78 |
| AstraZeneca | 3 | $55 |
| Chiesi USA, Inc. | 2 | $50 |
| Astellas Pharma US Inc | 2 | $41 |
| Boston Scientific | 1 | $39 |
| Lilly USA, LLC | 2 | $32 |
| Sandoz | 1 | $29 |
| Radius Health, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$149
- MINIMED 780G$105
How this compares
Too few endocrinology, diabetes & metabolism providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $196,140 |
| MounjaroTirzepatide | 118 | $126,794 |
| ForteoTeriparatide | 11 | $72,274 |
| JardianceEmpagliflozin | 81 | $67,584 |
| Humalog Kwikpen U-200Insulin Lispro | 23 | $63,327 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $53,200 |
| TrulicityDulaglutide | 50 | $48,451 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $32,648 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $32,039 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $31,751 |
| Humalog Kwikpen U-100Insulin Lispro | 66 | $22,436 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $20,291 |
| Novolog FlexpenInsulin Aspart | 46 | $14,780 |
| Praluent PenAlirocumab | 13 | $9,633 |
| KerendiaFinerenone | 15 | $9,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog, Insulin Lispro | $32 | $251,843222 claims |
| Novo NordiskOzempic, Novolog | $146 | $204,504189 claims |
| Boehringer IngelheimJardiance | $107 | $67,58481 claims |
| BayerKerendia | $78 | $9,53615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in North Dakotaon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Bismarck
- Bilal AhmedBismarck$7K
- William ZaksGrand Forks$63K
- Mario RiveraFargo$1K
- Raul Ruiz EspondaFargo$523
- Soamsiri NiwattisaiwongFargo$383
- David NewmanFargo$134
- Niyutchai ChaithongdiFargo$36
- William NewmanFargo$28
- Bharat RamanFargo$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.